PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
Jan Cools(KU Leuven), D. Gary Gilliland(Brigham and Women's Hospital), Jeffery L. Kutok(NKT Therapeutics (United States)), Thomas Meyer(Ansbach University of Applied Sciences), Doriano Fabbro(Novartis (Switzerland)), Paul W. Manley(Auckland City Hospital), Steven Coutré(Georgetown University), David P. Curley(Massachusetts General Hospital), Sonia M Amaral(Brigham and Women's Hospital), Christina Boulton(Brigham and Women's Hospital), Nicole Duclos(Brigham and Women's Hospital), Donna Neuberg(Otsuka (Japan)), Ellen Weisberg(Dana-Farber Cancer Institute), Elizabeth H. Stover(Dana-Farber Cancer Institute), Jason Gotlib(Stanford University), Benjamin H. Lee(Novartis (United States)), Richard M. Stone(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Ifor R. Williams(Emory University), Peter Marynen(Vlaams Instituut voor Biotechnologie), R. M. Rowan(Queen's University Belfast), James D. Griffin(Harvard University), Robert D. Legare(Brown University)
Cited by 218
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k